APA (7th ed.) Citation

Walter, E., Schmitt, T., Dietrich, S., Ho, A. D., & Witzens-Harig, M. (2012). Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leukemia and lymphoma, 53(11), . https://doi.org/10.3109/10428194.2012.682311

Chicago Style (17th ed.) Citation

Walter, Eva, Thomas Schmitt, Sascha Dietrich, Anthony Dick Ho, and Mathias Witzens-Harig. "Rituximab and Bendamustine in Patients with CD20+ Diffuse Large B-cell Lymphoma Not Eligible for Cyclophosphamide, Doxorubicin, Vincristine and Prednisone-like Chemotherapy." Leukemia and Lymphoma 53, no. 11 (2012). https://doi.org/10.3109/10428194.2012.682311.

MLA (9th ed.) Citation

Walter, Eva, et al. "Rituximab and Bendamustine in Patients with CD20+ Diffuse Large B-cell Lymphoma Not Eligible for Cyclophosphamide, Doxorubicin, Vincristine and Prednisone-like Chemotherapy." Leukemia and Lymphoma, vol. 53, no. 11, 2012, https://doi.org/10.3109/10428194.2012.682311.